Pages

▼

Pages

▼

Tuesday, January 26, 2021

McKinsey The risks and challenges of the global COVID-19-vaccine rollout

The scale is global. This requires a systems approach, which McKinsey is famous for.

McKinsey
The risks and challenges of the global COVID-19-vaccine rollout
Gaurav Agrawal, partner in McKinsey’s New York office; Tara Azimi, partner in the Washington, DC, office; Jennifer Heller and Parag Patel, partners in the Chicago office, Adam Sabow is a senior partner n the Chicago office; Pooja Kumar, partner in the Philadelphia office; Mihir Mysore, a partner in the Houston office; Shubham Singhal, a senior partner in the Detroit office; and Joseph Truesdale, associate partner in the Boston office.
at

6 comments:

  1. Peter PanJanuary 26, 2021 at 7:14 PM

    The risks are... failing to make enormous profit?

    ReplyDelete
  2. Matt FrankoJanuary 26, 2021 at 9:33 PM

    Merck cancelled theirs:

    https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/

    ReplyDelete
  3. Matt FrankoJanuary 26, 2021 at 9:34 PM

    Now increasing mRNA purchases:

    https://www.washingtonpost.com/health/2021/01/26/vaccine-supply-biden/

    ReplyDelete
  4. lastgreekJanuary 27, 2021 at 11:04 AM

    Universities should be doing the research and development, not these for-profit private corporations.

    ReplyDelete
  5. lastgreekJanuary 27, 2021 at 11:08 AM

    Pfizer, for example, runs a criminal enterprise on the side. This is not hyperbole. What would you call illegal off-label marketing of drugs?

    ReplyDelete
  6. Peter PanJanuary 28, 2021 at 3:51 AM

    ^ Import Export business.
    (Unless you find a bank that will help you in the laundering of your export).

    ReplyDelete